Edwards Lifesciences Corporation (NYSE: EW - Get Free Report) VP Donald Bobo, Jr. sold 22,680 shares of the stock in a transaction dated Thursday, April 2nd. The shares were sold at an average price of $80.16, for a total value of $1,818,028.80. Following the completion of the transaction, the vice president owned 21,266 shares in the

Cardiovascular disease may be one of medicine’s oldest battlegrounds, but some of its most important technologies are still evolving — and not always as...

Tilray Inc (NASDAQ:TLRY) earned a repeat ‘Buy’ rating from Jefferies analysts after what it described as a solid third quarter earnings report, pointing to...

Foundayo launches on April 6 at the same price as Novo's pill, threatening to reshape the $50 billion obesity drug market before Novo's first-quarter...

The forex market now turns over $9.6 trillion every single day. That figure, confirmed by the Bank for International Settlements in its 2025 Triennial...

Boston Common Asset Management LLC boosted its holdings in Edwards Lifesciences Corporation (NYSE: EW) by 6.7% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 144,703 shares of the medical research company's stock after buying an additional 9,028 shares during the quarter.

NEW ORLEANS--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced new data on the EVOQUE transcatheter tricuspid valve replacement (TTVR) system at the American College of Cardiology Annual Scientific Session (ACC.26), demonstrating significant and sustained patient benefits including lower mortality when accounting for patient crossover, extending the findings presented at the European Society of Cardiology Congress (ESC 2025). The new TRISCEND II trial data presented today during.

Edwards Lifesciences (NYSE: EW - Get Free Report) and ERBA Diagnostics (OTCMKTS:ERBA - Get Free Report) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, earnings, dividends, profitability and analyst recommendations. Institutional and Insider Ownership 79.5% of Edwards Lifesciences

Brevan Howard Capital Management LP lowered its stake in shares of Edwards Lifesciences Corporation (NYSE: EW) by 41.7% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 46,272 shares of the medical research company's stock after selling 33,100 shares during

Edwards Lifesciences delivered 11% revenue growth in 2025, driven by robust TAVR and accelerating TMTT businesses. Edwards Lifesciences guides for 8-10% sales growth and adjusted EPS of $2.90-$3.05 in 2026, with TMTT sales expected to rise 40%. Valuation has compressed to 26x forward earnings, supported by a strong net cash position and ongoing share repurchases.